Can you take NAD+ and BPC-157 together?

Last updated 2026-07-23

Can you take NAD+ and BPC-157 together?

Short answer: there's no research that has directly tested this combination, so anyone telling you it's proven safe (or proven risky) together is guessing past the data. That includes us. BPC-157 has a real, if entirely preclinical, research base. It's a synthetic pentadecapeptide derived from a protective protein found in human gastric juice, studied almost exclusively in rodent models for tissue and gut healing ^[1]. NAD+ (nicotinamide adenine dinucleotide) is a completely different molecule class, a coenzyme central to cellular energy metabolism, studied mostly in the context of aging, mitochondrial function, and IV/oral supplementation protocols. They don't share a metabolic pathway that's been mapped in any BPC-157 paper we could find. The honest position: no red flags exist in the literature, but that's because nobody has looked, not because someone looked and found it's fine. If you're already taking one and considering adding the other, the right move is running it by whoever is prescribing or supervising either compound, not a peptide forum.

What does the actual BPC-157 research show, separate from NAD+?

BPC-157's evidence base is overwhelmingly animal data. A 2025 literature and patent review in Pharmaceuticals covers its proposed roles across gut, wound, and musculoskeletal healing, and it's explicit that this is a synthesis of preclinical and patent literature, not a body of confirmed human trials ^[1]. A 2025 systematic review in HSS Journal looked specifically at BPC-157 in orthopaedic sports medicine and found the evidence supporting its use in tendon, ligament, and muscle injury is still dominated by animal studies, with human data lagging far behind the marketing claims circulating around it ^[2]. A 2019 mechanistic paper in Cell and Tissue Research describes how BPC-157 appears to accelerate musculoskeletal soft tissue healing in animal models, largely through effects on the local vascular and cellular repair response ^[3]. Human data does exist, but it's small and narrow. A 2021 report in Alternative Therapies in Health and Medicine looked at intra-articular BPC-157 injection for knee pain of multiple types, describing it as a pilot-scale clinical study, not a randomized controlled trial with the size to settle the question ^[4]. A separate 2024 pilot study in the same journal tested BPC-157 for symptoms in patients with interstitial cystitis, again a small pilot, not a definitive efficacy trial ^[5]. So when someone says 'the research shows BPC-157 heals tendons,' the accurate version is: rodent studies show that consistently, and two small human pilot studies exist for knee pain and interstitial cystitis specifically. That's the whole human record right now.

Is there any known interaction between NAD+ and BPC-157?

No published interaction study exists between these two compounds. We searched the BPC-157 literature specifically for any mention of NAD+, nicotinamide pathways, or NAD-dependent enzyme systems, and none of the primary papers reviewed here address it ^[1][2][6]. Mechanistically, the two don't obviously overlap. BPC-157's proposed effects run through angiogenesis and growth factor signaling, work summarized in a 2018 Current Pharmaceutical Design paper comparing BPC-157 to standard angiogenic growth factors in gut and connective tissue healing models ^[7], and through vascular effects described in a 2014 review on BPC-157 and blood vessels ^[8]. NAD+ protocols are built around mitochondrial energy metabolism and sirtuin activity, a different biochemical lane entirely. Absence of a documented interaction is not the same as a guarantee of safety. It just means this specific combination hasn't been the subject of a controlled study, in animals or people. If you want a first-principles read: two compounds with non-overlapping proposed mechanisms are less likely to clash than two that compete for the same receptor or enzyme, but 'less likely' isn't zero, and nobody has actually tested it.

What does BPC-157 dosing look like in the studies that exist?

This is where a lot of vendor copy goes wrong, so it's worth being precise. The rodent studies that make up most of the BPC-157 literature use doses calculated in micrograms per kilogram of body weight, scaled to rat or mouse physiology ^[3][9]. Those figures are not human dosing guidance, and no study has published a validated human dose-response protocol for BPC-157 in the way the FDA requires for approved drug products. The one human dosing data point worth naming specifically: the 2021 intra-articular knee pain study used a defined injection protocol into the joint space itself, distinct from the subcutaneous injection style commonly discussed online, and it was a pilot study, not a dose-finding trial ^[4]. A 2026 primer in The American Journal of Sports Medicine, aimed at orthopaedic and sports medicine physicians, frames injectable peptide therapies including BPC-157 as an emerging area physicians need a working vocabulary for, while being explicit that dosing standards across the field remain unsettled ^[10]. If you're trying to figure out how a compound like this is actually being used in supervised settings, the honest source is the bpc 157 dosage page, not a forum thread quoting a rat study.

Is BPC-157 legal, and does that change anything if you're combining it with NAD+?

BPC-157 is not FDA-approved for any use, a status you can confirm by checking the Drugs@FDA database, which lists no approved product under that name. That matters more than most sourcing pages let on. BPC-157 does not appear on the FDA's 503A bulk drug substances list under 21 CFR 216.23, nor the 503B bulks list under 21 CFR 216.24. In 2023, FDA placed BPC-157 in Category 2 on its nominated bulk substances list, meaning the agency identified significant safety concerns that argue against compounding it, a status you can verify on FDA's current nominated substances list. Practically, this means legitimate compounding pharmacies operate under the framework in 21 U.S.C. 353a, which governs when a licensed pharmacy can compound a preparation for an individual patient under a valid prescription. It does not mean BPC-157 is broadly cleared for compounding the way an approved drug's bulk substance would be. NAD+ has a more settled compounding history in some pharmacy contexts, but the same underlying rule applies: a legitimate product comes from a licensed pharmacy filling a provider's prescription, not a peptide reseller with no clinical oversight.

What do orthopaedic and sports medicine reviewers say about combining peptides like this?

The newest reviews in this space treat BPC-157 as one entry in a growing, loosely regulated category of injectable peptides, not a standalone therapy people should be mixing on their own. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine, titled 'Regeneration or Risk?', frames BPC-157 use for musculoskeletal healing as carrying real uncertainty alongside its regenerative promise, explicitly weighing potential benefit against unknowns in long-term safety ^[6]. A 2025 review in Arthroscopy asks directly whether injectable therapeutic peptides are a legitimate adjunct to regenerative medicine and sports performance, or getting ahead of what the data supports ^[11]. A forthcoming 2026 review in Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covers therapeutic peptides in orthopaedics broadly, discussing applications, challenges, and where the field needs better trials before adoption widens ^[12]. None of these papers discuss NAD+ specifically, but the pattern across all of them is consistent: peptide stacking without physician oversight is exactly the practice these reviewers are flagging as a challenge, not something the evidence currently supports doing casually.

What are the known side effects of BPC-157 that could complicate a combined protocol?

BPC-157's animal safety data suggests a wide margin between effective and toxic doses in rodent models, per the mechanistic review in Cell and Tissue Research ^[3], but that margin has never been formally established in humans through controlled trials. A 2011 study in the Journal of Applied Physiology, one of the foundational tendon-healing papers, found BPC-157 promoted tendon outgrowth, cell survival, and cell migration in an explant and in vivo rat model, describing a specific cellular mechanism rather than a generalized 'it heals everything' effect ^[13]. That specificity matters: a mechanism shown in tendon fibroblasts doesn't tell you anything about interaction risk with a coenzyme like NAD+. For a full rundown of documented and theoretical side effects reported across the BPC-157 literature, see bpc 157 peptide side effects. A 2026 review in Sports Medicine on the safety and efficacy of approved versus unapproved peptide therapies for musculoskeletal injuries makes the point plainly: unapproved peptides used off-label in athletic and injury-recovery contexts carry safety data gaps that approved drugs don't, precisely because they haven't gone through the FDA trial process ^[9]. Adding a second unregulated or loosely regulated compound like a NAD+ protocol onto an already understudied peptide compounds that same gap, not because of a known chemical clash, but because nobody is tracking the combined outcome data at all.

If there's no interaction data, how should someone actually decide?

Treat this as a risk-stacking question, not a chemistry question. Since no interaction study exists, the decision isn't 'is this combination proven safe,' it's 'am I comfortable adding a second understudied intervention on top of the first.' A few practical filters: First, is either compound being supervised by a licensed provider? If BPC-157 is coming through a legitimate route (a licensed compounding pharmacy filling a provider's prescription under 21 U.S.C. 353a), that provider is the right person to ask about adding NAD+, because they can see your full picture, more than the peptide literature. Second, what's the actual goal? If NAD+ is being used for a general energy or aging protocol and BPC-157 for a specific injury, stacking them doesn't obviously accelerate either goal, since they're not shown to work through the same pathway in any study reviewed here ^[1][7][8]. Third, sourcing quality matters more when you're combining anything. A product from an unverified online seller carries purity and dosing-accuracy risks on top of the unknown interaction question. If you're researching BPC-157 specifically, start with what's actually in the study record at bpc 157 peptide before layering in a second compound.

Where can you get BPC-157 through a legitimate, provider-reviewed process?

If a provider has decided BPC-157 is appropriate for your situation, the legitimate path is a prescription filled through a licensed compounding pharmacy, not a bulk peptide reseller shipping vials with no clinical review attached. BPC-157 Co's role here is narrow and worth being clear about: the site connects researchers and patients with provider-reviewed access, fulfilled through a licensed compounding pharmacy partner. BPC-157 Co does not compound anything itself. That distinction matters because compounding is a regulated pharmacy function under 21 U.S.C. 353a, and a pharmacy operating under that framework is accountable in a way an unregulated seller is not. If you're weighing sourcing options generally, bpc 157 for sale covers what separates a provider-reviewed pharmacy route from the gray-market alternatives, and that distinction becomes more important, not less, if you're planning to combine BPC-157 with anything else, NAD+ included.

Frequently asked questions

Can you take NAD+ and BPC-157 together safely?

No published study has tested this combination in animals or humans, so there's no direct safety data either way. The two compounds work through different, non-overlapping mechanisms in the papers reviewed here, which lowers the theoretical risk of a clash, but absence of a documented interaction isn't the same as proof of safety. Ask a supervising provider before combining.

Does BPC-157 interact with NAD+ supplements or NAD+ IV therapy?

There's no interaction study specific to NAD+ IV therapy or NAD+ supplements and BPC-157. The BPC-157 literature focuses on angiogenesis and tissue-repair pathways ^[5][12], while NAD+ research centers on mitochondrial energy metabolism, and none of the reviewed BPC-157 papers mention NAD+ pathways at all.

Is BPC-157 FDA-approved?

No. Checking the FDA's Drugs@FDA database shows no approved drug product under that name. BPC-157 also sits on FDA's Category 2 nominated bulk substances list, meaning the agency flagged significant safety concerns against compounding it, separate from the 503A and 503B bulk lists that govern legitimate pharmacy compounding.

What does the human research on BPC-157 actually show?

It's small and early. A 2021 pilot study in Alternative Therapies in Health and Medicine tested intra-articular BPC-157 injection for multiple types of knee pain, and a 2024 pilot study in the same journal tested it for interstitial cystitis symptoms. Neither is a large randomized trial, and most of the BPC-157 evidence base remains rodent studies, not human data.

Can BPC-157 dosing from rat studies be used to figure out a human dose?

No. Rodent studies dose BPC-157 in micrograms per kilogram scaled to rat or mouse physiology, and that math doesn't translate directly to human dosing. No published trial has established a validated human dose-response protocol for BPC-157, so any specific dose you see online is an extrapolation, not a proven human figure.

Are there known side effects of combining peptides like BPC-157 with other compounds?

No study has tracked combined outcomes for BPC-157 plus a second compound like NAD+. What's documented is that BPC-157 itself remains understudied in humans beyond two small pilot trials, and stacking any second unapproved or loosely regulated compound on top increases the amount of unmonitored variables in your own protocol, not because of a proven chemical interaction, but because nobody is collecting that data.

Is it legal to buy BPC-157 online?

It depends entirely on the source. BPC-157 isn't FDA-approved and sits in FDA's Category 2 nominated substances list, which argues against pharmacy compounding. A legitimate route runs through a licensed compounding pharmacy filling a valid prescription under 21 U.S.C. 353a; unregulated online resellers operate outside that framework entirely.

Does BPC-157 help with tendon or ligament healing?

In rodent models, yes, consistently. A 2011 study in the Journal of Applied Physiology found BPC-157 promoted tendon outgrowth, cell survival, and cell migration in rat tissue. A 2025 systematic review in HSS Journal found human evidence in orthopaedic sports medicine still lags well behind the animal data.

What's the difference between BPC-157 and NAD+ in terms of what they're studied for?

BPC-157 is studied mainly for gut lining protection and musculoskeletal soft tissue healing, almost entirely in rodent models with a small amount of human pilot data. NAD+ is studied mainly around cellular energy metabolism, mitochondrial function, and aging-related protocols. They're different molecule classes studied in largely separate research literatures.

Should I ask my doctor before combining NAD+ and BPC-157?

Yes. Since no interaction study exists for this specific combination, a provider who can see your full medical history and current protocols is the only person positioned to weigh the theoretical risk against your specific situation. This is especially true if either compound is being used at clinically meaningful doses rather than as a casual supplement.

Where does BPC-157 come from and how is it made?

BPC-157 is a synthetic pentadecapeptide, a lab-made version modeled on a protective sequence found in human gastric juice. It is not FDA-approved and is not naturally extracted from gastric fluid for commercial use; legitimate versions are made by licensed compounding pharmacies under a provider's prescription.

Is there a pilot study on BPC-157 for anything other than joints and tendons?

Yes. A 2024 pilot study published in Alternative Therapies in Health and Medicine tested BPC-157 for symptoms in patients with interstitial cystitis, a bladder condition, separate from the orthopaedic and knee-pain research. It was small-scale and described as a pilot, not a definitive efficacy trial.

Sources

1. PubMed, Pharmaceuticals (Basel), 2025, PMID 40005999: Literature and patent review describing BPC-157's proposed medical applications as based on preclinical and patent literature
2. PubMed, HSS Journal, 2025, PMID 40756949: Systematic review finding BPC-157 evidence in orthopaedic sports medicine is dominated by animal studies with limited human data
3. PubMed, Cell and Tissue Research, 2019, PMID 30915550: Mechanistic review of BPC-157 accelerating musculoskeletal soft tissue healing in animal models via vascular and cellular repair effects
4. PubMed, Alternative Therapies in Health and Medicine, 2021, PMID 34324435: Pilot study of intra-articular BPC-157 injection for multiple types of knee pain
5. PubMed, Current Pharmaceutical Design, 2018, PMID 29998800: Review comparing BPC-157 to standard angiogenic growth factors in gastrointestinal and connective tissue healing models
6. PubMed, Sports Medicine (Auckland), 2026, PMID 41966639: Review of safety and efficacy gaps between approved and unapproved peptide therapies used for musculoskeletal injuries
7. PubMed, Current Reviews in Musculoskeletal Medicine, 2025, PMID 40789979: Narrative review weighing BPC-157's regenerative promise against unresolved long-term safety uncertainty
8. PubMed, JAAOS Global Research & Reviews, 2026, PMID 41490200: Review of therapeutic peptides in orthopaedics covering applications, challenges, and need for better trials
9. PubMed, American Journal of Sports Medicine, 2026, PMID 41476424: Primer for orthopaedic and sports medicine physicians noting unsettled dosing standards for injectable peptides including BPC-157
10. PubMed, Arthroscopy, 2025, PMID 39265666: Review questioning whether injectable therapeutic peptides are a legitimate regenerative medicine adjunct given the current evidence
11. PubMed, Journal of Applied Physiology, 2011, PMID 21030672: Study finding BPC-157 promoted tendon outgrowth, cell survival, and cell migration in a rat model
12. PubMed, Current Pharmaceutical Design, 2014, PMID 23782145: Review of BPC-157's proposed effects on blood vessels and vascular signaling
13. PubMed, Alternative Therapies in Health and Medicine, 2024, PMID 39325560: Pilot study testing BPC-157 for symptoms in patients with interstitial cystitis
14. FDA, Bulk drug substances used in compounding under section 503A: BPC-157 does not appear on the FDA 503A bulk drug substances list for compounding
15. FDA, bulk drug substances nominated for use in compounding (current list): BPC-157 is listed in FDA Category 2, indicating significant safety concerns identified against compounding
16. Cornell Law, 21 U.S.C. 353a, pharmacy compounding: Statute governing when a licensed pharmacy may legally compound a preparation for an individual patient under a valid prescription
17. FDA, Drugs@FDA database: No FDA-approved drug product exists under the name BPC-157